Anuh Pharma Limited (BOM:506260)
India · Delayed Price · Currency is INR 82.12
-0.87 (-1.05%)
At close: Feb 12, 2026
Anuh Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
| 7,677 | 6,615 | 6,470 | 5,275 | 4,866 | 4,320 | |
Revenue Growth (YoY) | 22.38% | 2.24% | 22.66% | 8.39% | 12.66% | 40.72% |
Cost of Revenue | 6,042 | 5,067 | 4,914 | 4,075 | 3,809 | 3,329 |
Gross Profit | 1,634 | 1,548 | 1,556 | 1,200 | 1,057 | 990.23 |
Selling, General & Admin | 282.52 | 244.91 | 206.91 | 180.15 | 156.67 | 147.57 |
Other Operating Expenses | 736.67 | 655.21 | 594.25 | 486.85 | 417.13 | 394.33 |
Operating Expenses | 1,142 | 998.53 | 887.24 | 762.31 | 691.69 | 694.83 |
Operating Income | 492.89 | 549.51 | 668.73 | 437.21 | 365.35 | 295.4 |
Interest Expense | -4 | -6.19 | -3.54 | -2.18 | -9.61 | -14.95 |
Interest & Investment Income | 14.8 | 14.8 | 12.68 | 14.98 | 23.98 | 21.08 |
Currency Exchange Gain (Loss) | -27.81 | -27.81 | -2.86 | -21.46 | -16.49 | 3.02 |
Other Non Operating Income (Expenses) | 5.48 | 1.29 | 1.08 | 2.63 | 1.01 | 0.85 |
EBT Excluding Unusual Items | 481.35 | 531.59 | 676.1 | 431.17 | 364.24 | 305.4 |
Gain (Loss) on Sale of Investments | 78.3 | 78.3 | 107.21 | 43.39 | 26.37 | 80.44 |
Gain (Loss) on Sale of Assets | 0.17 | 0.17 | -0.22 | 0.15 | 0.62 | -0.32 |
Pretax Income | 559.82 | 610.05 | 783.1 | 474.7 | 391.22 | 385.51 |
Income Tax Expense | 141.6 | 136.53 | 182.52 | 112.91 | 85.61 | 101.15 |
Net Income | 418.22 | 473.52 | 600.58 | 361.8 | 305.61 | 284.36 |
Net Income to Common | 418.22 | 473.52 | 600.58 | 361.8 | 305.61 | 284.36 |
Net Income Growth | -16.78% | -21.16% | 66.00% | 18.38% | 7.47% | 98.78% |
Shares Outstanding (Basic) | 100 | 100 | 100 | 100 | 100 | 100 |
Shares Outstanding (Diluted) | 100 | 100 | 100 | 100 | 100 | 100 |
EPS (Basic) | 4.17 | 4.72 | 5.99 | 3.61 | 3.05 | 2.84 |
EPS (Diluted) | 4.17 | 4.72 | 5.99 | 3.61 | 3.05 | 2.84 |
EPS Growth | -16.71% | -21.16% | 66.00% | 18.38% | 7.47% | 98.78% |
Free Cash Flow | - | 169.79 | 79.09 | 523.52 | 272.49 | -248.89 |
Free Cash Flow Per Share | - | 1.69 | 0.79 | 5.22 | 2.72 | -2.48 |
Dividend Per Share | - | 0.750 | 1.250 | 1.000 | 0.875 | 0.750 |
Dividend Growth | - | -40.00% | 25.00% | 14.29% | 16.67% | 9.09% |
Gross Margin | 21.29% | 23.40% | 24.05% | 22.74% | 21.72% | 22.92% |
Operating Margin | 6.42% | 8.31% | 10.34% | 8.29% | 7.51% | 6.84% |
Profit Margin | 5.45% | 7.16% | 9.28% | 6.86% | 6.28% | 6.58% |
Free Cash Flow Margin | - | 2.57% | 1.22% | 9.93% | 5.60% | -5.76% |
EBITDA | 576.28 | 631.74 | 749.41 | 531.16 | 481.55 | 440.63 |
EBITDA Margin | 7.51% | 9.55% | 11.58% | 10.07% | 9.89% | 10.20% |
D&A For EBITDA | 83.39 | 82.23 | 80.68 | 93.95 | 116.2 | 145.23 |
EBIT | 492.89 | 549.51 | 668.73 | 437.21 | 365.35 | 295.4 |
EBIT Margin | 6.42% | 8.31% | 10.34% | 8.29% | 7.51% | 6.84% |
Effective Tax Rate | 25.29% | 22.38% | 23.31% | 23.79% | 21.88% | 26.24% |
Revenue as Reported | 7,776 | 6,710 | 6,591 | 5,336 | 4,918 | 4,425 |
Advertising Expenses | - | 8.05 | 7.37 | 3.17 | 0.18 | 0.18 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.